Angiotensin II Infusion for Shock: A Multicenter Study of Postmarketing Use

Abstract

Listen

Translate article

Vasodilatory shock refractory to catecholamine vasopressors and arginine vasopressin is highly morbid and responsible for significant mortality. Synthetic angiotensin II is a potent vasoconstrictor that may be suitable for use in these patients. What is the safety and effectiveness of angiotensin II and what variables are associated with a favorable hemodynamic response? We performed a multicenter, retrospective study at five tertiary medical centers in the United States. The primary end point of hemodynamic responsiveness to angiotensin II was defined as attainment of mean arterial pressure (MAP) of≥ 65mmHg with a stable or reduced total vasopressor dosage 3h after drug initiation. Of 270 included patients, 181 (67%) demonstrated hemodynamic responsiveness to angiotensin II. Responders showed a greater increase in MAP (+10.3mmHg vs+1.6mmHg, P< .001) and reduction in vasopressor dosage (-0.20 μg/kg/min vs+0.04 μg/kg/min; P< .001) compared with nonresponders at 3 h. Variables associated with favorable hemodynamic response included lower lactate concentration (OR 1.11; 95%CI, 1.05-1.17, P< .001) and receipt of vasopressin (OR, 6.05; 95%CI, 1.98-18.6; P= .002). In severity-adjusted multivariate analysis, hemodynamic responsiveness to angiotensin II was associated with reduced likelihood of 30-day mortality (hazard ratio, 0.50; 95%CI, 0.35-0.71; P< .001). Arrhythmias occurred in 28 patients (10%) and VTE was identified in 4 patients. In postmarketing use for vasopressor-refractory shock, 67%of angiotensin II recipients demonstrated a favorable hemodynamic response. Patients with lower lactate concentrations and those receiving vasopressin were more likely to respond to angiotensin II. Patients who responded to angiotensin II experienced reduced mortality.